Xenografts and Tumors

It was shown that CA-4-P (4) prodrug has underwent extensive predinical evaluation in human tumor xenografts and orthotopically transplanted tumors in murine models, demonstrating that the prodrug caused profound disruption of the tumor blood vessel network [66-74]. 

To examine the pathophysiological impact of treatment with combretastatin A-4-phosphate on the regions of tumors that ultimately either necrose or survive treatment with this agent, proliferation, perfusion, and expression of vascular endothelial growth factor (VEGF) were analyzed in the KHT tumor model after treatment with GA-4-P [2]. Analyses were conducted on the whole tumor and the tumor periphery. It was shown that perfusion in the tumor periphery decreased 4 h after treatment but returned to baseline 20 h later. Whole-tumor perfusion also 

---